NO982036D0 - Forbindelse egnet for behandling av traumatisk hjerneskade - Google Patents

Forbindelse egnet for behandling av traumatisk hjerneskade

Info

Publication number
NO982036D0
NO982036D0 NO982036A NO982036A NO982036D0 NO 982036 D0 NO982036 D0 NO 982036D0 NO 982036 A NO982036 A NO 982036A NO 982036 A NO982036 A NO 982036A NO 982036 D0 NO982036 D0 NO 982036D0
Authority
NO
Norway
Prior art keywords
treatment
brain injury
traumatic brain
compound suitable
compound
Prior art date
Application number
NO982036A
Other languages
English (en)
Other versions
NO982036L (no
Inventor
Brian R Pike
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO982036D0 publication Critical patent/NO982036D0/no
Publication of NO982036L publication Critical patent/NO982036L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO982036A 1995-11-06 1998-05-05 Forbindelse egnet for behandling av traumatisk hjerneskade NO982036L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
NO982036D0 true NO982036D0 (no) 1998-05-05
NO982036L NO982036L (no) 1998-06-25

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982036A NO982036L (no) 1995-11-06 1998-05-05 Forbindelse egnet for behandling av traumatisk hjerneskade

Country Status (18)

Country Link
EP (1) EP0866706A1 (no)
JP (1) JPH11514654A (no)
KR (1) KR19990067353A (no)
AU (1) AU706594B2 (no)
BG (1) BG63150B1 (no)
BR (1) BR9611396A (no)
CA (1) CA2234824A1 (no)
CZ (1) CZ287441B6 (no)
EA (1) EA000531B1 (no)
HU (1) HUP9901051A2 (no)
IS (1) IS4726A (no)
NO (1) NO982036L (no)
NZ (1) NZ321546A (no)
PL (1) PL326490A1 (no)
SK (1) SK58198A3 (no)
TR (1) TR199800801T2 (no)
WO (1) WO1997017074A1 (no)
ZA (1) ZA969320B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
BG63150B1 (bg) 2001-05-31
AU7490096A (en) 1997-05-29
AU706594B2 (en) 1999-06-17
NO982036L (no) 1998-06-25
MX9803432A (es) 1998-09-30
WO1997017074A1 (en) 1997-05-15
BG102480A (en) 1999-01-29
HUP9901051A2 (hu) 2000-03-28
SK58198A3 (en) 1998-10-07
PL326490A1 (en) 1998-09-28
ZA969320B (en) 1997-05-30
CZ138998A3 (cs) 1998-10-14
EP0866706A1 (en) 1998-09-30
CA2234824A1 (en) 1997-05-15
KR19990067353A (ko) 1999-08-16
JPH11514654A (ja) 1999-12-14
BR9611396A (pt) 1999-07-13
EA199800434A1 (ru) 1998-10-29
TR199800801T2 (xx) 1998-08-21
CZ287441B6 (en) 2000-11-15
IS4726A (is) 1998-04-27
EA000531B1 (ru) 1999-10-28
NZ321546A (en) 2000-12-22

Similar Documents

Publication Publication Date Title
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
FI964874A (fi) Vihannesten käsittely
NO934547D0 (no) Oral behandling av Helicobacter-in-feksjon
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO990225D0 (no) Medikamenter for behandling av hyperfosfatemi
FI962370A0 (fi) Laite tissuen valmistamiseksi
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
PT777457E (pt) A utilizacao de triacetato de glicerilo para o tratamento de onicomicoses
NO178150C (no) Ett-trinnsfremgangsmåte for fremstilling av diritromycin
NO972402D0 (no) Fremgangsmåte for fremstilling av bærere
NO975660D0 (no) Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av levkemi
NO982036D0 (no) Forbindelse egnet for behandling av traumatisk hjerneskade
NO930574D0 (no) Fremgangsmaate for fremstilling av desfluran
EE03384B1 (et) Melatoniini kasutamine ravimi tootmiseks
NO963187D0 (no) Fremgangsmåte for syntese av gamma-pyroner
NO982582D0 (no) FremgangsmÕte for behandling av smerte
EE9700235A (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
FI980091A0 (fi) Menetelmä ylijäämäaktiivilietteen käsittelemiseksi
NO955082L (no) Fremgangsmåte for fremstilling av glutardialdehyd
NO982562D0 (no) Sammensetning for behandling av smerte
NO963432D0 (no) Fremgangsmåte for fremstilling av dimetyldiklorsilan

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application